Singapore-based clinical research organisation (CRO) operating worldwide George Clinical announced on Mondaythat it is rebranded to become Emerald Clinical Trials.

The company claims that this strategic name change underscore its well-established position as a dedicated, reliable, consistent and flexible CRO, while mitigating global clinical development risks through deep therapeutic and local expertise cultivated over 20 years.

Emerald Clinical Trials continues to concentrate on end-to-end services across all therapeutic areas designed to change lives, while advancing innovations that help evolve global clinical research practices.